PortalPublikationenIn vivo T cell depletion with pretransplant anti-thymocyte g...

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.

Standard

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. / Kröger, N; Zabelina, Tatjana; Krüger, W; Renges, H; Stute, N; Rischewski, J; Sonnenberg, S; Ayuk, F; Ayuketang Ayuk, Francis; Schade, U; Fiegel, H; Erttmann, Rudolf; Löliger, C; Zander, A R.

in: BONE MARROW TRANSPL, Jahrgang 29, Nr. 8, 8, 2002, S. 683-689.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kröger, N, Zabelina, T, Krüger, W, Renges, H, Stute, N, Rischewski, J, Sonnenberg, S, Ayuk, F, Ayuketang Ayuk, F, Schade, U, Fiegel, H, Erttmann, R, Löliger, C & Zander, AR 2002, 'In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.', BONE MARROW TRANSPL, Jg. 29, Nr. 8, 8, S. 683-689. <http://www.ncbi.nlm.nih.gov/pubmed/12180114?dopt=Citation>

APA

Kröger, N., Zabelina, T., Krüger, W., Renges, H., Stute, N., Rischewski, J., Sonnenberg, S., Ayuk, F., Ayuketang Ayuk, F., Schade, U., Fiegel, H., Erttmann, R., Löliger, C., & Zander, A. R. (2002). In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. BONE MARROW TRANSPL, 29(8), 683-689. [8]. http://www.ncbi.nlm.nih.gov/pubmed/12180114?dopt=Citation

Vancouver

Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J et al. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors. BONE MARROW TRANSPL. 2002;29(8):683-689. 8.

Bibtex

@article{19f27bdeb02a4c61bcb6cdb67d3ac6b4,
title = "In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.",
abstract = "One-hundred and two patients with good risk myeloid leukemia (CML first chronic phase or AML first CR) were transplanted from HLA-related donors after conditioning with (n = 45) or without anti-thymocyte globulin (ATG) (n = 57). One graft failure was observed in the non-ATG and none in the ATG group. The median time to leukocyte engraftment (> 1 x 10(9)/l) was 16 (range 12-33) in the ATG group and 17 days (range 11-29) in the non-ATG group (NS) and for platelet engraftment (> 20 x 10(9)/l) 24 and 19 days (P = 0.002), respectively. Acute GVHD grade II-IV was observed in 47% of the non-ATG and in 20% of the ATG group (P = 0.004). Grade III/IV GVHD occurred in 7% of the ATG and in 32% of the non-ATG group (P = 0.002). Chronic GVHD was seen in 36% and 67% (P = 0.005), respectively. After a median follow-up of 48 months (range 2-128), the 5-year estimated OS is 66% (95% KI: 51-81%) for the ATG group and 59% (95% KI: 46-72%) for the non-ATG group (NS). The 5-year estimated DFS is 64% (95% KI: 50-78%) for ATG and 55% (95% KI: 43-67%) for the non-ATG regimen (NS). The 5-year probability of relapse was 5% in the ATG and 15% in the non-ATG group (NS). ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors.",
author = "N Kr{\"o}ger and Tatjana Zabelina and W Kr{\"u}ger and H Renges and N Stute and J Rischewski and S Sonnenberg and F Ayuk and {Ayuketang Ayuk}, Francis and U Schade and H Fiegel and Rudolf Erttmann and C L{\"o}liger and Zander, {A R}",
year = "2002",
language = "Deutsch",
volume = "29",
pages = "683--689",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "8",

}

RIS

TY - JOUR

T1 - In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.

AU - Kröger, N

AU - Zabelina, Tatjana

AU - Krüger, W

AU - Renges, H

AU - Stute, N

AU - Rischewski, J

AU - Sonnenberg, S

AU - Ayuk, F

AU - Ayuketang Ayuk, Francis

AU - Schade, U

AU - Fiegel, H

AU - Erttmann, Rudolf

AU - Löliger, C

AU - Zander, A R

PY - 2002

Y1 - 2002

N2 - One-hundred and two patients with good risk myeloid leukemia (CML first chronic phase or AML first CR) were transplanted from HLA-related donors after conditioning with (n = 45) or without anti-thymocyte globulin (ATG) (n = 57). One graft failure was observed in the non-ATG and none in the ATG group. The median time to leukocyte engraftment (> 1 x 10(9)/l) was 16 (range 12-33) in the ATG group and 17 days (range 11-29) in the non-ATG group (NS) and for platelet engraftment (> 20 x 10(9)/l) 24 and 19 days (P = 0.002), respectively. Acute GVHD grade II-IV was observed in 47% of the non-ATG and in 20% of the ATG group (P = 0.004). Grade III/IV GVHD occurred in 7% of the ATG and in 32% of the non-ATG group (P = 0.002). Chronic GVHD was seen in 36% and 67% (P = 0.005), respectively. After a median follow-up of 48 months (range 2-128), the 5-year estimated OS is 66% (95% KI: 51-81%) for the ATG group and 59% (95% KI: 46-72%) for the non-ATG group (NS). The 5-year estimated DFS is 64% (95% KI: 50-78%) for ATG and 55% (95% KI: 43-67%) for the non-ATG regimen (NS). The 5-year probability of relapse was 5% in the ATG and 15% in the non-ATG group (NS). ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors.

AB - One-hundred and two patients with good risk myeloid leukemia (CML first chronic phase or AML first CR) were transplanted from HLA-related donors after conditioning with (n = 45) or without anti-thymocyte globulin (ATG) (n = 57). One graft failure was observed in the non-ATG and none in the ATG group. The median time to leukocyte engraftment (> 1 x 10(9)/l) was 16 (range 12-33) in the ATG group and 17 days (range 11-29) in the non-ATG group (NS) and for platelet engraftment (> 20 x 10(9)/l) 24 and 19 days (P = 0.002), respectively. Acute GVHD grade II-IV was observed in 47% of the non-ATG and in 20% of the ATG group (P = 0.004). Grade III/IV GVHD occurred in 7% of the ATG and in 32% of the non-ATG group (P = 0.002). Chronic GVHD was seen in 36% and 67% (P = 0.005), respectively. After a median follow-up of 48 months (range 2-128), the 5-year estimated OS is 66% (95% KI: 51-81%) for the ATG group and 59% (95% KI: 46-72%) for the non-ATG group (NS). The 5-year estimated DFS is 64% (95% KI: 50-78%) for ATG and 55% (95% KI: 43-67%) for the non-ATG regimen (NS). The 5-year probability of relapse was 5% in the ATG and 15% in the non-ATG group (NS). ATG as part of the conditioning regimen leads to a significant reduction in GVHD without increase of relapse in patients with myeloid leukemia after stem cell transplantation from HLA-related donors.

M3 - SCORING: Zeitschriftenaufsatz

VL - 29

SP - 683

EP - 689

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 8

M1 - 8

ER -